| Capital Markets Industry | Financials Sector | Mr. Koen Dejonckheere Eng., M.B.A., M.Sc. CEO | XFRA Exchange | BE0003699130 ISIN |
| BE Country | 95 Employees | 1 Jun 2026 Last Dividend | 30 Jun 2025 Last Split | - IPO Date |
Gimv NV operates as a private equity and venture capital firm, engaging both in direct investments and fund of funds across a diverse range of fields. The firm is particularly adept at facilitating transformative growth through various forms of financial intervention, including buyouts, growth capital, bridge financing, and recapitalization, among others. With a primary focus on European markets, Gimv NV has honed its investment approach towards small to medium-sized enterprises, especially those within the regions of Flanders and Brussels, yet also extends its reach to countries like Kazakhstan, Benelux, Germany, France, Italy, Luxembourg, Netherlands, United Kingdom, Russia, Czech Republic, and Slovakia. The essence of Gimv NV's investment philosophy revolves around identifying and nurturing high-growth potential companies, particularly those considering internal growth acceleration via acquisitions or those in need of substantial financial restructuring to unlock their latent value.
Targeting emerging leaders in diverse consumer sectors from goods and services to digital economy and online sectors with growth capital. The aim is to shepherd these companies into dominant market positions through strategic financial and operational support.
Focusing on businesses that stand at the intersection of technology and consumer needs, fostering innovations that enhance connectivity and convenience in everyday consumer experiences.
Investing in financial technology companies poised for significant growth, leveraging innovations that disrupt traditional financial services with more efficient, accessible, and cost-effective solutions.
This platform is devoted to companies within the life sciences, medtech, and health and care services sectors, aiming at both organic growth and expansion through acquisitions. Areas of interest include biotech/biopharma, medical devices, and health services, offering potential for revolutionary impacts on health outcomes and care delivery.
Investment in industrial firms integrating smart technology to revolutionize production, efficiency, and sustainability, moving toward more innovative and automated solutions.
Supporting enterprises that contribute to the development of sustainable and livable cities, focusing on solutions that improve urban infrastructure, reduce environmental footprint, and enhance the quality of urban life.